Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions.
From: Departments of Radiation Oncology and Medicine, Cardiovascular Division, Brigham and Women’s Hospital and Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. adamico@lroc.harvard.edu
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publish Date: Jun 2007
- ISSN: 1527-7755
- Volume: 25
- Issue: 17
- Pages: 2420-5
- Medium: Internet
- Language: English
- Citation (JAMA): D'Amico Anthony V, Denham James W, Crook Juanita, et al. Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions.. J. Clin. Oncol. Jun 2007;25:2420-5
Abstract
PURPOSE: We evaluated whether the timing of fatal myocardial infarction (MI) was influenced by the administration of androgen suppression therapy (AST). PATIENTS AND METHODS: The study cohort comprised 1,372 men who were enrolled onto three randomized trials between February 1995 and June 2001. In the three trials, the men were randomly assigned to receive radiation therapy with 0 versus 3 versus 6, 3 versus 8, or 0 versus 6 months of AST. Fine and Gray’s regression was used to determine the clinical factors associated with the time to fatal MI, and estimates of time to fatal MI were calculated using a cumulative incidence method. When comparing the cumulative incidence estimates using Gray’s k-sample P values, increased weight was ascribed to the earlier data because recovery of testosterone is expected for most men within 2 years after short-course AST. RESULTS: Men age 65 years or older who received 6 months of AST experienced shorter times to fatal MIs compared with men in this age group who did not receive AST (P = .017) and men younger than 65 years (P = .016). No significant difference (P = .97) was observed in the time to fatal MIs in men age 65 years or older who received 6 to 8 months of AST compared with 3 months of AST. CONCLUSION: The use of AST is associated with earlier onset of fatal MIs in men age 65 years or older who are treated for 6 months compared with men who are not treated with AST.
Mesh Headings (Keywords): Age Factors, Aged, Androgen Antagonists, Humans, Male, Middle Aged, Myocardial Infarction, Prostatic Neoplasms, Randomized Controlled Trials as Topic, Risk Factors
Check for Full Text / PubMed Unique Identifier (PMID): 17557956
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.